Other
Apremilast
Phosphodiesterase-4 inhibitor (non-biologic)
Other names: Otezla
Wait
2 weeks
ground trial when starting
Other FAA documents add more.
Examiner
The examiner can issue when the document's criteria are met
FAA label
ACCEPTABLE
The FAA's biologics sheet lists apremilast as acceptable monotherapy medication when the underlying condition qualifies, with a two-week ground trial when starting and no no-fly time after later doses, and a note to report any signs of depression.
Track your medicationsCompare FAA documents: apremilastWhat each of the two FAA documents says, in plain wordsOpen
Wait
- no wait after later doses
The FAA's CACI – Arthritis Worksheet lists it (PDE4) among its acceptable medications as any single medication after a 2-week ground trial, with no post-dose observation time, and says the examiner can issue if the pilot meets all of its acceptable certification criteria.
- 14 days after starting: ground observation
Show the FAA's words: apremilastThe official FAA wording: two passages, each with its document and dateOpen
Initial observation: All require a 2-week no-fly/ground trial to verify no side effects.
ACCEPTABLE BIOLOGICS - MONOTHERAPY MEDICATION Permitted if the underlying condition qualifies; consult the condition pages for details.
Non-Biologic Medications Post-dose Observation No-Fly times
Phosphodiesterase-4 Enzyme Inhibitor: apremilast (Otezla). Report any signs of depression, None
If the applicant meets ALL the acceptable certification criteria listed below, the AME can issue
Phosphodiesterase-4 Enzyme Inhibitor (PDE4)
Any singe medication listed below after a 2-week ground trial and:
No post-dose observation time:
PDE4: apremilast (Otezla)